RightFit Trial Directory

Parkinson's Disease clinical trials in Fort Worth, TX

5 recruiting parkinson's disease studies with a site in Fort Worth, TX.

All trials in Fort Worth, TX · All Parkinson's Disease trials

RecruitingPhase 3NCT06312176

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Sponsor: Merck Sharp & Dohme LLC

Dallas, TX · +43 more sites

RecruitingPhase 3NCT06952504

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Sponsor: Merck Sharp & Dohme LLC

Fort Worth, TX · Houston, TX · San Antonio, TX · +50 more sites

RecruitingPhase 3NCT06966700

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Sponsor: Merck Sharp & Dohme LLC

Abilene, TX · Dallas, TX · +61 more sites

RecruitingPhase 3NCT06989112

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Sponsor: AstraZeneca

Austin, TX · Fort Worth, TX · Houston, TX · +60 more sites

RecruitingPhase 3NCT07216703

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Sponsor: Merck Sharp & Dohme LLC

Fort Worth, TX · Houston, TX · The Woodlands, TX · +27 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.